Get notified when GTBP files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Delisting (new) — Company faces potential delisting from Nasdaq for failing to maintain minimum $1.00 bid price requirement.
GT Biopharma gets 180-day extension to regain Nasdaq compliance, faces delisting risk
Filed May 22, 2026 · Period ending May 20, 2026 · ~1 min read
Key Changes
-
high
Nasdaq granted GT Biopharma until November 16, 2026 to regain compliance with the $1.00 minimum bid price requirement. Stock must close at $1.00+ for 10 consecutive business days to avoid delisting.
Item 3.01 verify on EDGAR → -
high
Company originally fell out of compliance in November 2025 after trading below $1.00 for 30 straight days. The initial 180-day grace period expired May 19, 2026 without regaining compliance.
Item 3.01 verify on EDGAR → -
medium
GT Biopharma qualified for the extension because it meets all other Nasdaq Capital Market listing requirements including market value of publicly held shares, except for the minimum bid price.
Item 3.01 verify on EDGAR →
1 more material change behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (ADMT 10-K) is open in full — no account needed.
Partner
Trade GTBP commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Source-verified from EDGAR · Narrative written by AI · May 25, 2026 · How we verify